MBA Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$517K Sell
562
-6
-1% -$6.08K 0.2% 81
2025
Q4
$610K Buy
568
+33
+6% +$31.6K 0.25% 75
2025
Q3
$408K Buy
535
+15
+3% +$11.2K 0.17% 96
2025
Q2
$405K Sell
520
-4
-0.8% -$3.11K 0.19% 94
2025
Q1
$433K Buy
524
+41
+8% +$34.1K 0.21% 82
2024
Q4
$373K Sell
483
-1
-0.2% -$828 0.19% 90
2024
Q3
$429K Sell
484
-73
-13% -$65.6K 0.21% 84
2024
Q2
$504K Sell
557
-33
-6% -$26.4K 0.26% 73
2024
Q1
$459K Sell
590
-549
-48% -$391K 0.24% 78
2023
Q4
$664K Buy
1,139
+29
+3% +$16.9K 0.37% 64
2023
Q3
$596K Sell
1,110
-142
-11% -$73.2K 0.37% 62
2023
Q2
$587K Hold
1,252
0.35% 65
2023
Q1
$430K Hold
1,252
0.27% 78
2022
Q4
$458K Hold
1,252
0.3% 74
2022
Q3
$405K Hold
1,252
0.29% 74
2022
Q2
$406K Buy
1,252
+2
+0.2% +$600 0.28% 76
2022
Q1
$358K Sell
1,250
-102
-8% -$26.3K 0.22% 100
2021
Q4
$373K Buy
1,352
+18
+1% +$4.56K 0.23% 100
2021
Q3
$308K Sell
1,334
-102
-7% -$25.2K 0.23% 99
2021
Q2
$330 Sell
1,436
-28
-2% -$5.62K 0.15% 96
2021
Q1
$274 Buy
+1,464
New +$286K 0.15% 105

Other funds holding LLY

MBA Advisors's LLY Position: Q1 2026 in Review

MBA Advisors reduced its Eli Lilly (LLY) stake by 1.1% in Q1 2026, selling an estimated $6.08K and leaving 562 shares worth $517K. The position accounts for 0.2% of the portfolio, ranked #81.

MBA Advisors first reported a position in LLY in Q1 2021 and has held it in 21 quarters since. The position peaked at $664K in Q4 2023. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • MBA Advisors held 562 shares of Eli Lilly worth $517K as of Q1 2026.
  • MBA Advisors sold 6 Eli Lilly shares in Q1 2026, an estimated $6.08K.
  • Eli Lilly made up 0.2% of MBA Advisors's portfolio in Q1 2026, its #81 holding.
  • MBA Advisors first reported a position in Eli Lilly in Q1 2021 and has held it in 21 quarters since.
  • MBA Advisors's Eli Lilly position peaked at $664K in Q4 2023.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on MBA Advisors's 13F filing for Q1 2026, filed 20 Apr 2026.